Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetMiguel Á. Sanz, Francesco Lo‐Coco, Eva Lengfelder et al.|Blood|2019Cited by 655
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia Ling, John Allen, Edwin Lau et al.|Haematologica|2011Cited by 129
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform TrialSun Loo, Andrew H. Wei, Harry Iland et al.|Blood|2024Cited by 9